Abstract
Antibodies are emerging as a new drug class with many of these approved and marketed. Antibodies may be non-human, chimeric, humanized or fully human. All these have the potential to elicit an immune response in the host which may impact on safety and efficacy. Therefore, assessment of immunogenicity of the therapeutic protein is an essential part of its clinical development. This involves testing strategies which provide relevant information on antibody responses. This chapter describes a simple ELISA method to detect human anti-antibody response.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Aarden L, Ruuls SR, Wolbink G (2008) Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 20:431–435
Avramis VI, Avramis EV, Hunter W, Long MC (2009) Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res 29:299–302
Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343–357
De Groot AS, Scott DW (2007) Immunogenicity of protein therapeutics. Trends Immunol 28:482–490
Findlay JW, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, Khan MN, Bowsher RR (2000) Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 21:1249–1273
Geng D, Shankar G, Schantz A, Rajadhyaksha M, Davis H, Wagner C (2005) Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal 39:364–375
Hale G (2006) Therapeutic antibodies – delivering the promise? Adv Drug Deliv Rev 58:633–639
Horninger D, Eirikis E, Pendley C, Giles-Komar J, Davis HM, Miller BE (2005) A one-step, competitive electrochemiluminescence-based immunoassay method for the quantification of a fully human anti-TNFalpha antibody in human serum. J Pharm Biomed Anal 38:703–708
Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, Barrett YC, Devanarayan V, Gorovits B, Gupta S, Parish T, Quarmby V, Moxness M, Swanson SJ, Taniguchi G, Zuckerman LA, Stebbins CC, Mire-Sluis A (2008) Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 333:1–9
Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA (2004) Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289:1–16
Presta LG (2006) Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58:640–656
Schellekens H (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720–1740
Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147–159
Shankar G, Pendley C, Stein KE (2007) A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25:555–561
Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E (2008) Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 48:1267–1281
Sharma SK, Bagshawe KD, Melton RG, Sherwood RF (1992) Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys 21:109–120
Thorpe R, Swanson SJ (2005) Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin Diagn Lab Immunol 12:28–39
Wadhwa M, Thorpe R (2006) Strategies and assays for the assessment of unwanted immunogenicity. J Immunotoxicol 3:115–121
Wadhwa M, Bird C, Dilger P, Gaines-Das R, Thorpe R (2003) Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods 278:1–17
White JT, Martell LA, Van TA, Boyer R, Warness L, Taniguchi GT, Foehr E (2008) Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase). AAPS J 10:363–372
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this protocol
Cite this protocol
Griffin, N.L., Shahbakhti, H., Sharma, S.K. (2010). Human Anti-antibody Response. In: Kontermann, R., Dübel, S. (eds) Antibody Engineering. Springer Protocols Handbooks. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01147-4_38
Download citation
DOI: https://doi.org/10.1007/978-3-642-01147-4_38
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-01146-7
Online ISBN: 978-3-642-01147-4
eBook Packages: Springer Protocols